Keyphrases
Glucose-dependent Insulinotropic Polypeptide
100%
Glucagon-like
70%
Glucose-dependent Insulinotropic Polypeptide Receptor
41%
Type 2 Diabetic Patients
39%
Type 2 Diabetes Mellitus (T2DM)
31%
A1 Receptor
26%
Receptor Antagonist
25%
Healthy Individuals
24%
Placebo
23%
Postprandial Glucose
18%
Glucos
17%
Glucagon
17%
Exendin (9-39)
15%
Food Intake
14%
Randomized Placebo-controlled Trial
14%
Metabolic Effects
14%
Meal Tolerance Test
13%
Acarbose
11%
Bone Resorption
11%
Incretin Hormones
10%
Glucose Tolerance
10%
Glucose Effect
10%
Receptor Activation
9%
Appetite Sensations
9%
Bone Metabolism
9%
Liver-expressed Antimicrobial Peptide 2
9%
Insulin Secretion
9%
Placebo-controlled
8%
Receptor Antagonism
8%
Energy Expenditure
8%
Polypeptide 1
8%
Oral Glucose Tolerance Test
8%
Fibroblast Growth Factor 21 (FGF21)
8%
Gut-bone Axis
7%
Cell Function
7%
Energy Intake
7%
Alcohol Administration
7%
Intravenous Alcohol
7%
Ethanol Infusion
7%
Postprandial Effect
7%
Plasma Glucose
7%
Metformin
7%
Growth Hormone Secretagogue Receptor (GHS-R)
7%
Bone Homeostasis
7%
Ad Libitum
6%
Ad Libitum Food Intake
6%
Hemoglobin A1c (HbA1c)
6%
Ghrelin
6%
Fasting Plasma Glucose
6%
Glucose-lowering Drugs
6%
Medicine and Dentistry
Gastric Inhibitory Polypeptide
63%
Glucagon Like Peptide 1
33%
Maturity Onset Diabetes of the Young
29%
Patient with Type 2 Diabetes
27%
Placebo
27%
Food Intake
22%
Infusion
19%
Receptor
17%
Glucagon Like Peptide 1 Receptor
17%
Receptor Antagonist
14%
Osteolysis
11%
Incretin
11%
Glucose Tolerance
11%
Diabetes
10%
Exendin 9
10%
Test Meal
10%
Meal
9%
Hepcidin
9%
Sensation
8%
Gut
8%
Obesity
8%
COVID-19
7%
Cell Function
7%
Acarbose
7%
Glucagon
7%
Oral Glucose Tolerance Test
7%
Ghrelin Receptor
7%
Glycon
6%
Glucose Metabolism
6%
Ghrelin
6%
Homeostasis
6%
Alcohol Consumption
5%
Pathophysiology
5%
Glucagon-Like Peptide-1 Agonist
5%
Pharmacology, Toxicology and Pharmaceutical Science
Gastric Inhibitory Polypeptide
74%
Non Insulin Dependent Diabetes Mellitus
46%
Gastric Inhibitory Polypeptide Receptor
37%
Placebo
36%
Glucagon-Like Peptide-1
33%
Receptor Antagonist
24%
Glucagon-Like Peptide 1 Receptor
20%
Exendin 9
12%
Obesity
12%
Acarbose
11%
Incretin
10%
Metformin
8%
Tirzepatide
5%
Glucagon Like Peptide 1 Receptor Agonist
5%